Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Abstract
The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FGF21 is an important therapeutic target of protection against muscle and liver insulin resistance induced by lipids and DM2.
“As such, it is an important therapeutic target of protection against muscle and liver insulin resistance induced by lipids and DM2 [106,107].”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [106]
FGF21 is essential for controlling glucose and lipid metabolism.
“Substances that act as adipokines, myokines, and hepatokines, such as FGF21, are essential for controlling glucose and lipid metabolism.”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [106]
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782 · see citing works
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · see citing works
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016 · see citing works
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · see citing works
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883 · see citing works
Receptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871 · see citing works
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865 · see citing works
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,846 · see citing works
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh‐Hain, J. A., Tamez, H. E., Shah, A., Smith, K. T., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,729 · see citing works
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649 · see citing works
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504 · see citing works
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,503 · see citing works
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · see citing works
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · see citing works
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.101545198 · Cited by 1,391 · see citing works
Shimada, T., Kakitani, M., Yamazaki, Y., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419081 · Cited by 1,368 · see citing works
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho*
Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K., Baum, M., Schiavi, S., Hu, M.-C., Moe, O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500457200 · Cited by 1,356 · see citing works
Receptor Specificity of the Fibroblast Growth Factor Family
Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601252200 · Cited by 1,164 · see citing works
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works
Evolution of the Fgf and Fgfr gene families.
Itoh, N., & Ornitz, D. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.08.007 · Cited by 1,123 · see citing works
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · see citing works
The parathyroid is a target organ for FGF23 in rats
Ben‐Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R. M., Kuro‐o, M., Mohammadi, M., Sirkis, R., Naveh‐Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951 · see citing works
Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7473 · Cited by 943 · see citing works
Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., et al. (2008) · Diabetes · doi:10.2337/db07-1476 · Cited by 908 · see citing works
Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R. J., Larsson, T. E., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 904 · see citing works
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · see citing works
Identification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847 · see citing works
Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K. A., Smith, K. T., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E. E., Christenson, R. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 840 · see citing works
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830 · see citing works
Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans
Lee, P., Linderman, J. D., Smith, S., Brychta, R. J., Wang, J., Idelson, C., Perron, R. M., Werner, C. D., Phan, G. Q., Kammula, U. S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.017 · Cited by 802 · see citing works
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748 · see citing works
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · see citing works
Structural basis for fibroblast growth factor receptor activation
Mohammadi, M., Olsen, S. K., & Ibrahimi, O. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.008 · Cited by 737 · see citing works
Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704 · see citing works
Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700 · see citing works
Holt, J. A., Luo, G., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K., Donahee, M. H., Wang, D. Y., Mansfield, T. A., Kliewer, S. A., et al. (2003) · Genes & Development · doi:10.1101/gad.1083503 · Cited by 698 · see citing works
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · see citing works
Yamazaki, Y., Okazaki, R., Shibata, M., Hasegawa, Y., Satoh, K., Tajima, T., Takeuchi, Y., Fujita, T., Nakahara, K., Yamashita, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021105 · Cited by 670 · see citing works
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
Riminucci, M., Collins, M. T., Fedarko, N. S., Cherman, N., Corsi, A., White, K. E., Waguespack, S. G., Gupta, A., Hannon, T. S., Econs, M. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18399 · Cited by 656 · see citing works
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Kir, S., Beddow, S. A., Samuel, V. T., Miller, P., Previs, S. F., Suino-Powell, K., Xu, H. E., Shulman, G. I., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Science · doi:10.1126/science.1198363 · Cited by 637 · see citing works
Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose Tissue
Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F. J., Giralt, M., Mampel, T., & Villarroya, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215889 · Cited by 623 · see citing works
βKlotho is required for metabolic activity of fibroblast growth factor 21
Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Goetz, R., Eliseenkova, A. V., Mohammadi, M., & Kuro-o, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701600104 · Cited by 617 · see citing works
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607 · see citing works
FGF21 is an endocrine signal of protein restriction
Laeger, T., Henagan, T. M., Albarado, D. C., Redman, L. M., Bray, G. A., Noland, R. C., Münzberg, H., Hutson, S. M., Gettys, T. W., Schwartz, M. W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74915 · Cited by 593 · see citing works
Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., & Potthoff, M. J. (2014) · Diabetes · doi:10.2337/db14-0595 · Cited by 590 · see citing works
Fu, L., John, L. M., Adams, S. H., Yu, X. X., Tomlinson, E., Renz, M. E., Williams, P. M., Soriano, R. H., Corpuz, R. T., Moffat, B., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1671 · Cited by 580 · see citing works
Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule
Hu, M. C., Shi, M., Zhang, J., Pastor, J. V., Nakatani, T., Lanske, B., Razzaque, M. S., Rosenblatt, K. P., Baum, M. G., Kuro‐o, M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-154765 · Cited by 579 · see citing works
Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., et al. (2002) · Endocrinology · doi:10.1210/endo.143.5.8850 · Cited by 576 · see citing works
Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G. L., Kliewer, S., & Gonzalez, F. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700330-jlr200 · Cited by 575 · see citing works
Yamashita, T., Yoshioka, M., & Itoh, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3696 · Cited by 553 · see citing works
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Bookout, A. L., de Groot, M. H. M., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3249 · Cited by 545 · see citing works
Goetz, R., Beenken, A., Ibrahimi, O., Kalinina, J., Olsen, S., Eliseenkova, A. V., Xu, C.-F., Neubert, T., Zhang, F.-M., Linhardt, R., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02249-06 · Cited by 544 · see citing works
Dutchak, P. A., Katafuchi, T., Bookout, A. L., Choi, J. H., Yu, R. T., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell · doi:10.1016/j.cell.2011.11.062 · Cited by 537 · see citing works
An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
Holland, W., Adams, A., Brozinick, J., Bui, H., Miyauchi, Y., Kusminski, C., Bauer, S., Wade, M., Singhal, E., Cheng, C. C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.019 · Cited by 525 · see citing works
FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss
Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523 · see citing works
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512 · see citing works
Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX
Liu, S., Guo, R., Simpson, L. G., Xiao, Z.-S., Burnham, C. E., & Quarles, L. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304544200 · Cited by 505 · see citing works
Wente, W., Efanov, A. M., Brenner, M. B., Kharitonenkov, A., Koster, A. M., Sandusky, G. E., Sewing, S., Treinies, I., Zitzer, H., & Gromada, J. (2006) · Diabetes · doi:10.2337/db05-1435 · Cited by 497 · see citing works
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
White, K. E., Carn, G., Lorenz‐Depiereux, B., Benet‐Pagès, A., Strom, T. M., & Econs, M. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00064.x · Cited by 488 · see citing works
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
Benet-Pagès, A., Orlik, P., Strom, T., & Lorenz-Depiereux, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi034 · Cited by 486 · see citing works
Diabetes mellitus and genetically programmed defects in β-cell function
Bell, G. I., & Polonsky, K. S. (2001) · Nature · doi:10.1038/414788a · Cited by 475 · see citing works
Kong, B., Wang, L., Chiang, J. Y. L., Zhang, Y., Klaassen, C. D., & Guo, G. L. (2012) · Hepatology · doi:10.1002/hep.25740 · Cited by 456 · see citing works
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
Potthoff, M. J., Kliewer, S. A., & Mangelsdorf, D. J. (2012) · Genes & Development · doi:10.1101/gad.184788.111 · Cited by 442 · see citing works
Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J., & Naveh‐Many, T. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00360.2010 · Cited by 440 · see citing works
Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A. S., Busuttil, R. W., Yee, H. T., Stein, L. D., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 437 · see citing works
FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
Potthoff, M. J., Boney-Montoya, J., Choi, M., He, T., Sunny, N. E., Satapati, S., Suino-Powell, K., Xu, H. E., Gerard, R. D., Finck, B. N., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.019 · Cited by 431 · see citing works
Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.102 · Cited by 429 · see citing works
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426 · see citing works
The starvation hormone, fibroblast growth factor-21, extends lifespan in mice
Zhang, Y., Xie, Y., Berglund, E. D., Coate, K. C., He, T. T., Katafuchi, T., Xiao, G., Potthoff, M. J., Wei, W., Wan, Y., et al. (2012) · eLife · doi:10.7554/elife.00065 · Cited by 420 · see citing works
Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J. L., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61405 · Cited by 417 · see citing works
FGF21 is an Akt‐regulated myokine
Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., & Walsh, K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.021 · Cited by 415 · see citing works
Song, K., Li, T., Owsley, E., Strom, S. C., & Chiang, J. Y. L. (2008) · Hepatology · doi:10.1002/hep.22627 · Cited by 414 · see citing works
Functional evolutionary history of the mouse Fgf gene family
Itoh, N., & Ornitz, D. M. (2007) · Developmental Dynamics · doi:10.1002/dvdy.21388 · Cited by 409 · see citing works
Inhibition of Growth Hormone Signaling by the Fasting-Induced Hormone FGF21
Inagaki, T., Lin, V. Y., Goetz, R., Mohammadi, M., Mangelsdorf, D. J., & Kliewer, S. A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.05.006 · Cited by 409 · see citing works
Kolek, O. I., Hines, E. R., Jones, M. D., LeSueur, L., Lipko, M. A., Kiela, P. R., Collins, J. F., Haussler, M. R., & Ghishan, F. K. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2005 · Cited by 408 · see citing works
Lundåsen, T., Gälman, C., Angelin, B., & Rudling, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01731.x · Cited by 406 · see citing works
βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism
Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.002 · Cited by 403 · see citing works
Fibroblast growth factor 21 protects against cardiac hypertrophy in mice
Planavila, A., Redondo‐Angulo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R., Gabrielli, L., Sitges, M., Giralt, M., van Bilsen, M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3019 · Cited by 371 · see citing works
PPARα is a key regulator of hepatic FGF21
Lundåsen, T., Hunt, M., Nilsson, L.-M., Sanyal, S., Angelin, B., Alexson, S., & Rudling, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.068 · Cited by 361 · see citing works
A Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359 · see citing works
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism
Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., Ono, K., Kakitani, M., Tomizuka, K., Fujita, T., et al. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00474.2004 · Cited by 359 · see citing works
Yu, C., Wang, F., Kan, M., Jin, C., Jones, R. B., Weinstein, M., Deng, C.-X., & Mckeehan, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.15482 · Cited by 357 · see citing works
Mirza, M. A. I., Larsson, A. O., Melhus, H., Lind, L., & Larsson, T. E. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.013 · Cited by 341 · see citing works
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · see citing works
Bai, X., Miao, D., Li, J., Goltzman, D., & Karaplis, A. C. (2004) · Endocrinology · doi:10.1210/en.2004-0233 · Cited by 329 · see citing works
FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho
Kharitonenkov, A., Dunbar, J. D., Bina, H. A., Bright, S. W., Moyers, J. S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S. F., Knierman, M. D., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21357 · Cited by 329 · see citing works
Hagel, M., Miduturu, C., Sheets, M. P., Rubin, N. T., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B. L., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 326 · see citing works
A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid Biosynthesis
Walters, J. R. F., Tasleem, A. M., Omer, O. S., Brydon, W. G., Dew, T. K., & le Roux, C. W. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.04.024 · Cited by 318 · see citing works
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Carpenter, T. O., Imel, E. A., Ruppe, M. D., Weber, T. J., Klausner, M. A., Wooddell, M. M., Kawakami, T., Ito, T., Zhang, X., Humphrey, J. S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72829 · Cited by 313 · see citing works
Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives
Woo, Y. C., Xu, A., Wang, Y., & Lam, K. S. L. (2012) · Clinical Endocrinology · doi:10.1111/cen.12095 · Cited by 302 · see citing works
FGF-19, A NOVEL FIBROBLAST GROWTH FACTOR WITH UNIQUE SPECIFICITY FOR FGFR4
Xie, M.-H., Holcomb, I. N., Deuel, B., Dowd, P., Huang, A. J. Y., Vagts, A. J., Foster, J., Liang, J., Brush, J., Gu, Q., et al. (1999) · Cytokine · doi:10.1006/cyto.1999.0485 · Cited by 301 · see citing works
Liang, Q., Zhong, L., Zhang, J., Wang, Y., Bornstein, S. R., Triggle, C. R., Ding, H., Lam, K. S. L., & Xu, A. (2014) · Diabetes · doi:10.2337/db14-0541 · Cited by 299 · see citing works
Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A., & Wasserman, D. H. (2009) · Endocrinology · doi:10.1210/en.2009-0221 · Cited by 297 · see citing works
Muise, E. S., Azzolina, B., Kuo, D. W., El-Sherbeini, M., Tan, Y., Yuan, X., Mu, J., Thompson, J. R., Berger, J. P., & Wong, K. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.044826 · Cited by 294 · see citing works
Identification of a hormonal basis for gallbladder filling
Choi, M., Moschetta, A., Bookout, A., Peng, L., Umetani, M., Holmstrom, S. R., Suino-Powell, K., Xu, H. E., Richardson, J., Gerard, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1501 · Cited by 289 · see citing works
Sarruf, D. A., Thaler, J. P., Morton, G. J., German, J. P., Fischer, J. D., Ogimoto, K., & Schwartz, M. W. (2010) · Diabetes · doi:10.2337/db09-1878 · Cited by 287 · see citing works
Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21
Owen, B. M., Mangelsdorf, D. J., & Kliewer, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.10.002 · Cited by 286 · see citing works
Liver-specific Activities of FGF19 Require Klotho beta
Lin, B. C., Wang, M., Blackmore, C. A., & Desnoyers, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704244200 · Cited by 284 · see citing works
Nitta, M., Ku, S., Brown, C., Okamoto, A. Y., & Shan, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6660 · Cited by 283 · see citing works
Schaap, F. G., Gaag, N. A. V. D., Gouma, D. J., & Jansen, P. L. M. (2008) · Hepatology · doi:10.1002/hep.22771 · Cited by 279 · see citing works
Mraz, M., Bartlova, M., Lacinova, Z., Michalsky, D., Kasalicky, M., Haluzikova, D., Matoulek, M., Dostalova, I., Humenanska, V., & Haluzik, M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03502.x · Cited by 279 · see citing works
Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.028 · Cited by 275 · see citing works
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism
Quarles, L. D. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.218 · Cited by 268 · see citing works
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue
Adams, A. C., Yang, C., Coskun, T., Cheng, C. C., Gimeno, R. E., Luo, Y., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2012.08.007 · Cited by 266 · see citing works
Desnoyers, L. R., Pai, R., Ferrando, R., Hotzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 266 · see citing works
Fibroblast growth factor 21 protects the heart from oxidative stress
Planavila, A., Redondo‐Angulo, I., Ribas‐Aulinas, F., Garrabou, G., Casademont, J., Giralt, M., & Villarroya, F. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu263 · Cited by 265 · see citing works
Komaba, H., Goto, S., Fujii, H., Hamada, Y., Kobayashi, A., Shibuya, K., Tominaga, Y., Otsuki, N., Nibu, K., Nakagawa, K., et al. (2009) · Kidney International · doi:10.1038/ki.2009.414 · Cited by 264 · see citing works
Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia
Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090509 · Cited by 264 · see citing works
Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho
Ito, S., Fujimori, T., Furuya, A., Satoh, J., Nabeshima, Y., & Nabeshima, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23076 · Cited by 248 · see citing works
Itoh, N. (2010) · Cell and Tissue Research · doi:10.1007/s00441-010-1024-2 · Cited by 247 · see citing works
Galitzer, H., Ben‐Dov, I. Z., Silver, J., & Naveh‐Many, T. (2009) · Kidney International · doi:10.1038/ki.2009.464 · Cited by 246 · see citing works
Interplay between FGF21 and insulin action in the liver regulates metabolism
Emanuelli, B., Vienberg, S. G., Smyth, G., Cheng, C., Stanford, K. I., Arumugam, M., Michael, M. D., Adams, A. C., Kharitonenkov, A., & Kahn, C. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67353 · Cited by 243 · see citing works
Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain
Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H., & Itoh, N. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00255-3 · Cited by 235 · see citing works
McWhirter, J. R., Goulding, M., Weiner, J. A., Chun, J. J. M., & Murre, C. (1997) · Development · doi:10.1242/dev.124.17.3221 · Cited by 231 · see citing works
FGF21 contributes to neuroendocrine control of female reproduction
Owen, B. M., Bookout, A. L., Ding, X., Lin, V. Y., Atkin, S. D., Gautron, L., Kliewer, S. A., & Mangelsdorf, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3250 · Cited by 230 · see citing works
Andrukhova, O., Zeitz, U., Goetz, R. M., Mohammadi, M., Lanske, B., & Erben, R. G. (2012) · Bone · doi:10.1016/j.bone.2012.05.015 · Cited by 228 · see citing works
Relationship between circulating FGF23 and total body atherosclerosis in the community
Mirza, M. A. I., Hansen, T., Johansson, L. O. M., Ahlström, H. K., Larsson, A. O., Lind, L., & Larsson, T. E. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp205 · Cited by 223 · see citing works
Keipert, S., Ost, M., Johann, K., Imber, F., Jastroch, M., van Schothorst, E. M., Keijer, J., & Klaus, S. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2013 · Cited by 221 · see citing works
FGF19 action in the brain induces insulin-independent glucose lowering
Morton, G. J., Matsen, M. E., Bracy, D. P., Meek, T. H., Hồng, N. T., Stefanovski, D., Bergman, R. N., Wasserman, D. H., & Schwartz, M. W. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70710 · Cited by 220 · see citing works
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, D., Lin, B. C., Wang, M.-T., Adams, C. W., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216 · see citing works
Regulation of Bile Acid Synthesis by Fat-soluble Vitamins A and D
Schmidt, D. R., Holmstrom, S. R., Tacer, K. F., Bookout, A. L., Kliewer, S. A., & Mangelsdorf, D. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116004 · Cited by 211 · see citing works
Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004690 · Cited by 211 · see citing works
Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis
Bhatnagar, S., Damron, H. A., & Hillgartner, F. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808818200 · Cited by 209 · see citing works
Pharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue
Véniant, M. M., Sivits, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C., & Lloyd, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.019 · Cited by 204 · see citing works
Tsuji, K., Maeda, T., Kawane, T., Matsunuma, A., & Horiuchi, N. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.65 · Cited by 203 · see citing works
Ohnishi, M., Nakatani, T., Lanske, B., & Razzaque, M. S. (2009) · Kidney International · doi:10.1038/ki.2009.24 · Cited by 199 · see citing works
Inventing new medicines: The FGF21 story
Kharitonenkov, A., & Adams, A. C. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.003 · Cited by 198 · see citing works
Hesse, M., Fröhlich, L. F., Zeitz, U., Lanske, B., & Erben, R. G. (2006) · Matrix Biology · doi:10.1016/j.matbio.2006.10.003 · Cited by 198 · see citing works
Anti-FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23
Yamazaki, Y., Tamada, T., Kasai, N., Urakawa, I., Aono, Y., Hasegawa, H., Fujita, T., Kuroki, R., Yamashita, T., Fukumoto, S., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080417 · Cited by 195 · see citing works
Touchberry, C., Green, T. M., Tchikrizov, V., Mannix, J., Mao, T. F., Carney, B. W., Girgis, M., Vincent, R. J., Wetmore, L. A., Dawn, B., et al. (2013) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.00596.2012 · Cited by 195 · see citing works
Miura, S., Mitsuhashi, N., Shimizu, H., Kimura, F., Yoshidome, H., Otsuka, M., Kato, A., Shida, T., Okamura, D., & Miyazaki, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-56 · Cited by 193 · see citing works
Li, H., Gao, Z., Zhang, J., Ye, X., Xu, A., Ye, J., & Jia, W. (2012) · Diabetes · doi:10.2337/db11-0846 · Cited by 193 · see citing works
Ryan, K. K., Kohli, R., Gutierrez-Aguilar, R., Gaitonde, S. G., Woods, S. C., & Seeley, R. J. (2013) · Endocrinology · doi:10.1210/en.2012-1891 · Cited by 185 · see citing works
Wu, A.-L., Coulter, S., Liddle, C., Wong, A., Eastham‐Anderson, J., French, D. M., Peterson, A. S., & Sonoda, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017868 · Cited by 185 · see citing works
Wu, A.-L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., Phamluong, K., Feng, B., Li, L., Marsters, S., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002669 · Cited by 184 · see citing works
FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets
Imel, E. A., Hui, S. L., & Ecibs, M. J. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070107 · Cited by 183 · see citing works
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Zhou, M., Wang, X., Phung, V., Lindhout, D. A., Mondal, K., Hsu, J.-Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0208 · Cited by 183 · see citing works
FGF21 Requires βklotho to Act In Vivo
Adams, A. C., Cheng, C. C., Coskun, T., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049977 · Cited by 181 · see citing works
Wang, H., Qiang, L., & Farmer, S. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00992-07 · Cited by 181 · see citing works
Barthel, T. K., Mathern, D. R., Whitfield, G. K., Haussler, C. A., Hopper, H. A., Hsieh, J., Slater, S. A., Hsieh, G., Kaczmarska, M. J., Jurutka, P. W., et al. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.12.054 · Cited by 180 · see citing works
Fibroblast Growth Factor 21 Reduces the Severity of Cerulein-Induced Pancreatitis in Mice
Johnson, C. L., Weston, J. Y., Chadi, S. A., Fazio, E. N., Huff, M. W., Kharitonenkov, A., Köester, A., & Pin, C. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.064 · Cited by 180 · see citing works
Lin, Z., Wu, Z., Yin, X., Liu, Y., Yan, X., Lin, S., Xiao, J., Wang, X., Feng, W., & Li, X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015534 · Cited by 179 · see citing works
Endocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose Tissue
Liu, S. Q., Roberts, D., Kharitonenkov, A., Zhang, B., Hanson, S., Li, Y. C., Zhang, L., & Wu, Y. (2013) · Scientific Reports · doi:10.1038/srep02767 · Cited by 179 · see citing works
Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W. L., & Luo, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033870 · Cited by 173 · see citing works
Yu, H., Xia, F., Lam, K. S., Wang, Y., Bao, Y., Zhang, J., Gu, Y., Zhou, P., Lu, J., Jia, W., et al. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155184 · Cited by 170 · see citing works
LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys
Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065763 · Cited by 169 · see citing works
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
Kharitonenkov, A., Beals, J. M., Micanovic, R., Strifler, B. A., Rathnachalam, R., Wroblewski, V. J., Li, S., Köester, A., Ford, A. M., Coşkun, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058575 · Cited by 168 · see citing works
Marcelin, G., Jo, Y., Li, X., Schwartz, G. J., Zhang, Y., Dun, N. J., Lyu, R., Blouet, C., Chang, J. K., & Chua, S. C. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.10.002 · Cited by 168 · see citing works
A nontumorigenic variant of FGF19 treats cholestatic liver diseases
Luo, J., Ko, B., Elliott, M., Zhou, M. L., Lindhout, D. A., Phung, V., To, C., Learned, R. M., Tian, H., DePaoli, A. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009098 · Cited by 167 · see citing works
Hecht, R. I., Li, Y., Sun, J., Belouski, E., Hall, M. P., Hager, T., Yie, J., Wang, W., Winters, D., Smith, S. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049345 · Cited by 166 · see citing works
FGF21-based pharmacotherapy – potential utility for metabolic disorders
Gimeno, R. E., & Moller, D. E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.03.001 · Cited by 163 · see citing works
Mu, J., Pinkstaff, J. K., Li, Z., Skidmore, L. K., Li, N., Myler, H. A., Dallas-Yang, Q., Hays, A. A., Yao, J., Bussell, S., et al. (2011) · Diabetes · doi:10.2337/db11-0838 · Cited by 162 · see citing works
Cyphert, H. A., Ge, X., Kohan, A. B., Salati, L. M., Zhang, Y., & Hillgartner, F. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.375907 · Cited by 161 · see citing works
Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156 · see citing works
Schreuder, T. C. M. A., Marsman, H. A., Leníček, M., van Werven, J. R., Nederveen, A. J., Jansen, P. L. M., & Schaap, F. G. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00322.2009 · Cited by 156 · see citing works
Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1
Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.046 · Cited by 154 · see citing works
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0111 · Cited by 153 · see citing works
Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription
Meir, T., Durlacher, K., Pan, Z., Amir, G., Richards, W. G., Silver, J., & Naveh-Many, T. (2014) · Kidney International · doi:10.1038/ki.2014.215 · Cited by 152 · see citing works
Lee, Y.-K., Schmidt, D. R., Cummins, C. L., Choi, M., Peng, L., Zhang, Y., Goodwin, B. J., Hammer, R. E., Mangelsdorf, D. J., & Kliewer, S. A. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0565 · Cited by 151 · see citing works
The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis
Haussler, M. R., Whitfield, G. K., Kaneko, I., Forster, R. E., Saini, R. K., Hsieh, J., Haussler, C. A., & Jurutka, P. W. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9199-8 · Cited by 151 · see citing works
Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients
González‐Parra, E., González‐Casaus, M. L., Galan, A., Martínez-Calero, A., Navas, V., Rodríguez, M., & Ortíz, A. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr144 · Cited by 151 · see citing works
Yu, X., Sabbagh, Y., Davis, S. I., Demay, M. B., & White, K. E. (2005) · Bone · doi:10.1016/j.bone.2005.03.002 · Cited by 149 · see citing works
Targeted Deletion of Klotho in Kidney Distal Tubule Disrupts Mineral Metabolism
Olauson, H., Lindberg, K., Amin, R., Jia, T., Wernerson, A. M., Andersson, G. N., & Larsson, T. E. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010048 · Cited by 148 · see citing works
Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys
Véniant, M. M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. I., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2012-1211 · Cited by 147 · see citing works
Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice
Razzaque, M. S., & Lanske, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.05.002 · Cited by 145 · see citing works
Stroup, D., & Chiang, J. Y. L. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32068-x · Cited by 145 · see citing works
Wright, T. J., Ladher, R., Mcwhirter, J., Murre, C., Schoenwolf, G., & Mansour, S. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.02.003 · Cited by 144 · see citing works
Relevant use of Klotho in FGF19 subfamily signaling system in vivo
Tomiyama, K.-I., Maeda, R., Urakawa, I., Yamazaki, Y., Tanaka, T., Ito, S., Nabeshima, Y., Tomita, T., Odori, S., Hosoda, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913986107 · Cited by 143 · see citing works
Adams, A. C., Astapova, I. I., Fisher, F. M., Badman, M. K., Kurgansky, K. E., Flier, J. S., Hollenberg, A. N., & Maratos–Flier, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.107375 · Cited by 141 · see citing works
Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling
Wu, X., Ge, H., Gupte, J., Weiszmann, J., Shimamoto, G., Stevens, J., Hawkins, N., Lemon, B., Shen, W., Xu, J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700130200 · Cited by 140 · see citing works
Nuclear Receptors HNF4α and LRH-1 Cooperate in Regulating Cyp7a1 in Vivo
Kır, S., Zhang, Y., Gerard, R. D., Kliewer, S. A., & Mangelsdorf, D. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421834 · Cited by 137 · see citing works
Koizumi, M., Komaba, H., Nakanishi, S., Fujimori, A., & Fukagawa, M. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr384 · Cited by 135 · see citing works
Bile acid malabsorption in inflammatory bowel disease
Martin Lenicek, A., Ďuricová, D., Komárek, V., Gabrysova, B., Lukáš, M., Šmerhovský, Z., & Vı́tek, L. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21502 · Cited by 130 · see citing works
Miao, J., Xiao, Z., Kanamaluru, D., Min, G., Yau, P. M., Veenstra, T. D., Ellis, E. C. S., Strom, S., Suino-Powell, K. M., Xu, H. E., et al. (2009) · Genes & Development · doi:10.1101/gad.1773909 · Cited by 126 · see citing works
Recent advances in renal phosphate handling
Farrow, E., & White, K. E. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.17 · Cited by 125 · see citing works
Chemical generation of bispecific antibodies
Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., van Hagen, C., Levin, N. J., Shields, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016478108 · Cited by 124 · see citing works
FGF21 mediates the lipid metabolism response to amino acid starvation
De Sousa-Coelho, A. L., Relat, J., Hondares, E., Pérez-Martí, A., Ribas, F., Villarroya, F., Marrero, P. F., & Haro, D. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033415 · Cited by 123 · see citing works
Huang, J., Ishino, T., Chen, G., Rolzin, P., Osothprarop, T. F., Retting, K., Li, L., Jin, P., Matin, M. J., Huyghe, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204420 · Cited by 121 · see citing works
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121 · see citing works
Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating β-Catenin Signaling
Pai, R., Dunlap, D. Y., Qing, J., Mohtashemi, I., Hötzel, K., & French, D. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2325 · Cited by 121 · see citing works
Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa
Dostálová, I., Kaválková, P., Haluzíková, D., Lacinová, Z., Mráz, M., Papežová, H., & Haluzı́k, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0746 · Cited by 111 · see citing works
So, W. Y., Cheng, Q., Chen, L., Evans‐Molina, C., Xu, A., Lam, K. S. L., & Leung, P. S. (2013) · Diabetes · doi:10.2337/db13-0645 · Cited by 109 · see citing works
Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)
Wu, X., Ge, H., Lemon, B. D., Vonderfecht, S. L., Baribault, H., Weiszmann, J., Gupte, J., Gardner, J., Lindberg, R. A., Wang, Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009427107 · Cited by 104 · see citing works
Yu, C., Wang, F., Jin, C., Huang, X., & McKeehan, W. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411771200 · Cited by 103 · see citing works
Glucocorticoids Regulate the Metabolic Hormone FGF21 in a Feed-Forward Loop
Patel, R., Bookout, A. L., Magomedova, L., Owen, B. M., Consiglio, G. P., Shimizu, M., Zhang, Y., Mangelsdorf, D. J., Kliewer, S. A., & Cummins, C. L. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1259 · Cited by 102 · see citing works
Molecular interactions of FGF23 and PTH in phosphate regulation
Lanske, B., & Razzaque, M. S. (2014) · Kidney International · doi:10.1038/ki.2014.316 · Cited by 102 · see citing works
Li, Y., Wong, K., Walsh, K., Gao, B., & Zang, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.429852 · Cited by 101 · see citing works
Circadian expression of FGF21 is induced by PPARα activation in the mouse liver
Oishi, K., Uchida, D., & Ishida, N. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.09.046 · Cited by 95 · see citing works
Hyeon, J., Ahn, S., Lee, J. J., Song, D. H., & Park, C.-K. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2609-x · Cited by 94 · see citing works
Marco, G. S. D., Reuter, S., Kentrup, D., Grabner, A., Amaral, A. P., Fobker, M., Stypmann, J., Pavenstädt, H., Wolf, M. S., Faul, C., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu190 · Cited by 92 · see citing works
FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov, A., & Shanafelt, A. B. (2009) · PubMed · Cited by 91 · see citing works
Li, S., Hsu, D. D., Li, B., Luo, X., Alderson, N. B., Qiao, L., Ma, L., Zhu, H. H., He, Z., Suino-Powell, K. M., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.020 · Cited by 90 · see citing works
Hondares, E., Gallego-Escuredo, J. M., Flachs, P., Frontini, A., Cereijo, R., Goday, A., Perugini, J., Kopecky, P., Giralt, M., Cinti, S., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.11.014 · Cited by 90 · see citing works
Ileal FGF 15 contributes to fibrosis‐associated hepatocellular carcinoma development
Uriarte, I., Latasa, M. U., Carotti, S., Fernández‐Barrena, M. G., García‐Irigoyen, O., Elizalde, M., Urtasun, R., Gentilucci, U. V., Morini, S., Pulido, Á. D. M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29287 · Cited by 88 · see citing works
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
Wu, X., Ge, H., Lemon, B. D., Weiszmann, J., Gupte, J., Hawkins, N., Li, X., Tang, J., Lindberg, R. A., & Li, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907812106 · Cited by 88 · see citing works
C-terminal Tail of FGF19 Determines Its Specificity toward Klotho Co-receptors
Wu, X., Lemon, B. D., Li, X., Gupte, J., Weiszmann, J., Stevens, J. L., Hawkins, N., Shen, W. D., Lindberg, R. A., Chen, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803319200 · Cited by 86 · see citing works
FGF 21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation
Yan, X., Chen, J., Zhang, C., Zhou, S., Zhang, Z., Chen, J., Feng, W., Li, X., & Tan, Y. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12530 · Cited by 85 · see citing works
Mráz, M., Lacinová, Z., Kaválková, P., Haluzíková, D., Trachta, P., Drápalová, J., Hanušová, V., & Haluzı́k, M. (2011) · Physiological Research · doi:10.33549/physiolres.932099 · Cited by 82 · see citing works
Flagged first, then by citations
1 of the 240 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Abou‐Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G. M., Melisi, D., Al-Rajabi, R. M. T., Paulson, A. S., Borad, M. J., Gallinson, D. H., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,634 · see citing works
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,617 · see citing works
“, 2016), therapies that increase hepatic ketogenesis could prove salutary (Degirolamo et al., 2016; Honda et al., 2016).”
BackgroundFGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904 · see citing works
“Endocrine FGFs, encoded by FGF19 subfamily gene, which bind and activate FGFRs with the Klotho family protein, regulate a wide range of metabolic processes.(692) Based on the structure–function principle, separating mitogenic and metabolic activities of FGF19 through mutagenesis of five N-terminal and heparin-binding…”
BackgroundAdvances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.8 · Cited by 815 · see citing works
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · see citing works
“Increases in visceral adipose tissue (VAT) have been associated with dyslipidemia (Després et al., 1990), insulin resistance (Couillard et al.”
Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631 · see citing works
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607 · see citing works
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306256 · Cited by 573 · see citing works
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 507 · see citing works
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 513 · see citing works
Bile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 440 · see citing works
“However, FGF21 may potentially be utilized as a therapeutic to treat obesity and metabolic disease (21, 37, 130).”
BackgroundHarrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425 · see citing works
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Katoh, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405 · see citing works
“FGF23 is upregulated by serum phosphate, vitamin D and parathyroid hormone in bone to trans-duce endocrine signaling through FGFR1 and α -Klotho in the kidneys and negative feedback signaling through FGFR3 and α -Klotho in the parathyroid gland (118).”
Gu, Y., Wang, X., Li, J., Zhang, Y., Zhong, H., Liu, R., Zhang, D., Feng, Q., Xie, X., Hong, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01682-2 · Cited by 396 · see citing works
Goyal, L., Shi, L., Liu, L. Y., de la Cruz, F. F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0182 · Cited by 384 · see citing works
“Hyperphosphatemia is a class effect of FGFR inhibitors arising from on-target pathway blockade of FGF23– FGFR1 signaling in the renal tubule (22, 36).”
BackgroundMazzaferro, V., El‐Rayes, B. F., Busset, M. D. D., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0334-0 · Cited by 366 · see citing works
The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration
Farooq, M., Khan, A. W., Kim, M., & Choi, S.-D. (2021) · Cells · doi:10.3390/cells10113242 · Cited by 342 · see citing works
“FGF23, aside from being a phosphaturic hormone, serves as an important regulator of calcium and sodium reabsorption in the kidney [69].”
BackgroundTargeting the alternative bile acid synthetic pathway for metabolic diseases
Jia, W. P., Wei, M., Rajani, C., & Zheng, X. (2020) · Protein & Cell · doi:10.1007/s13238-020-00804-9 · Cited by 329 · see citing works
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Dai, S., Zhou, Z. M., Chen, Z., Xu, G., & Chen, Y. (2019) · Cells · doi:10.3390/cells8060614 · Cited by 297 · see citing works
“Although nonselective inhibitors might be clinically beneficial and achieve therapeutic success to some extent, the development of those inhibitors has been restricted due to the undesirable off-target toxicities [80,81].”
BackgroundBile acid signaling pathways from the enterohepatic circulation to the central nervous system
Mertens, K. L., Kalsbeek, A., Soeters, M. R., & Eggink, H. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00617 · Cited by 287 · see citing works
“In addition, it should be studied to which extend the different FGFs contribute to the FGFRs signaling in the CNS, because FGF21 binds to the same FGFR and β-Klotho complexes as FGF19 and generates similar effects when administered in the brain (Owen et al., 2015; Degirolamo et al., 2016).”
BackgroundHarrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280 · see citing works
The Ever-Expanding Myokinome: Discovery Challenges and Therapeutic Implications
Whitham, M., & Febbraio, M. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.153 · Cited by 279 · see citing works
Kim, R. D., Sarker, D., Meyer, T., Yau, T. C. C., Macarulla, T. M., Park, J., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0555 · Cited by 276 · see citing works
“FGFR4 pathway activation by FGF19 promotes bile acid production from cholesterol (24).”
BackgroundFibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270 · see citing works
Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262 · see citing works
“(4) Fibroblast growth factor 19 (FGF19), an endocrine gastrointestinal hormone, controls bile acid metabolism through actions on cholesterol 7alpha-hydroxylase (CYP7A1), the first and rate-limiting enzyme in the classic pathway of bile acid synthesis from cholesterol.(5) Multiple independent groups have reported reduc…”
BackgroundGut microbiota in the pathogenesis and therapeutic approaches of diabetes
Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104821 · Cited by 251 · see citing works
Self-citationMechanisms of muscle insulin resistance and the cross‐talk with liver and adipose tissue
Rosa, S. C. D. S., Nayak, N., Caymo, A. M., & Gordon, J. W. (2020) · Physiological Reports · doi:10.14814/phy2.14607 · Cited by 251 · see citing works
“and lipid metabolism, as well as the whole-body homeostasis (Degirolamo et al., 2016).”
BackgroundStructures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Lee, S., Choi, J., Mohanty, J., Sousa, L. P., Tome, F., Pardon, E., Steyaert, J., Lemmon, M. A., Lax, I., & Schlessinger, J. (2018) · Nature · doi:10.1038/nature25010 · Cited by 236 · see citing works
Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice
Benoit, B., Meugnier, E., Castelli, M., Chanon, S., Vieille-Marchiset, A., Durand, C., Bendridi, N., Pesenti, S., Monternier, P.-A., Durieux, A.-C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4363 · Cited by 225 · see citing works
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
Saeed, A., Dullaart, R. P. F., Schreuder, T. C. M. A., Blokzijl, H., & Faber, K. N. (2017) · Nutrients · doi:10.3390/nu10010029 · Cited by 229 · see citing works
“FGF19 suppresses lipogenesis by blocking SREBP-1c signaling and simultaneously inducing fatty acid β-oxidation by blocking ACC2 (reviewed in [154]).”
BackgroundNew therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227 · see citing works
“In addition to M70, several other FGF mimetics are available, which are, however, not yet explored for cholestasis.((55)) Administration of M70 in healthy human volunteers potently reduced serum levels of 7a-hydroxy-4cholesten-3-one (C4) as a surrogate marker for hepatic CYP7A1 activity((56)) (Table 1).”
Genetic insights into the mechanisms of Fgf signalingPreprint
Brewer, J. R., Mazot, P., & Soriano, P. M. (2016) · Genes & Development · doi:10.1101/gad.277137.115 · Cited by 224 · see citing works
“Several therapeutic strategies are currently being developed to modulate Fgfr signaling in various pathologies (Carter et al. 2015; Degirolamo et al. 2016).”
BackgroundTillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 209 · see citing works
“Post prandial suppression of adipose tissue lipolysis by insulin is impaired(48),whileuptakebyadipose tissueofdietary fat as chylomicrons is also attenuated.”
BackgroundTherapeutics Targeting FGF Signaling Network in Human Diseases
Katoh, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.003 · Cited by 206 · see citing works
“FGF21 (LY2405319) [9_TD$DIFF] GF21 [14_TD$DIFF] receptor T2DM P1 (NCT01869959) [57]”
BackgroundInfluentialNovel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works
Subbiah, V., Iannotti, N. O., Gutierrez, M. E., Smith, D. C., Féliz, L. R., Lihou, C. F., Tian, C., Silverman, I. M., Ji, T., & Saleh, M. N. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.001 · Cited by 201 · see citing works
“26 Although our results showed that concentrations of both phosphate and FGF23 increased after pemigatinib dosing, FGF23 concentration remained elevated during dosing holidays, whereas phosphate concentrations fell below baseline, suggesting that elevated FGF23 concentrations may be responsible for…”
Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis
Jia, W. P., Li, Y., Cheung, K. C.-P., & Zheng, X. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2353-0 · Cited by 201 · see citing works
“Fibroblast growth factor 21 (FGF21) is a nutrient-sensing hormone that is produced in response to prolonged fasting in hepatocytes and adipose tissues, and was associated with BA levels and composition (Degirolamo et al., 2016).”
Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.035 · Cited by 187 · see citing works
“Ethnic origin, n (%) Hispanic/Latino 0 1 (5) 0”
BackgroundInfluentialAdipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052639 · Cited by 189 · see citing works
Targeting FGFR inhibition in cholangiocarcinoma
Goyal, L., Kongpetch, S., Crolley, V. E., & Bridgewater, J. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102170 · Cited by 183 · see citing works
“important role in phosphate homeostasis [68,69] and FGFR1 is the predominant receptor for the hypophosphatemic action of FGF23 in vivo [70].”
BackgroundPathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 180 · see citing works
FXR in liver physiology: Multiple faces to regulate liver metabolism
Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 160 · see citing works
Kumar, V., Xin, X., Ma, J., Tan, C., Osna, N. A., & Mahato, R. I. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113888 · Cited by 160 · see citing works
Zhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152 · see citing works
“Moreover, FGF19 has also been implicated in the systemic control of triglycerides, cholesterol, glucose, and energy homeostasis((16)) in addition to mediating regulation of de novo bile acid synthesis.”
BackgroundRoles of FGF Signals in Heart Development, Health, and Disease
Itoh, N., Ohta, H., Nakayama, Y., & Konishi, M. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00110 · Cited by 152 · see citing works
“FGF9 possesses novel therapeutic potential due to its ability to mediate monocyte to M2 macrophage differentiation and confer cardiac protection in the post-myocardial infarction diabetic heart (Singla et al., 2015).”
BackgroundSkeletal muscle energy metabolism in obesity
Mengeste, A. M., Rustan, A. C., & Lund, J. (2021) · Obesity · doi:10.1002/oby.23227 · Cited by 141 · see citing works
New developments in the biology of fibroblast growth factors
Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 143 · see citing works
Harrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 148 · see citing works
Structural basis for FGF hormone signalling
Chen, L., Fu, L., Sun, J., Huang, Z., Fang, M., Zinkle, A., Liu, X., Lu, J., Pan, Z., Wang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06155-9 · Cited by 147 · see citing works
“Lastly, we studied the possibility of FGFR heterodimerization by paracrine FGFs by focusing on: (1) FGFR1c–FGFR4 and FGFR1b–FGFR2b heterodimerizations by FGF1; (2) FGFR1b–FGFR2b heterodimerization by FGF10; and (3) FGFR2b–FGFR3b heterodimerization by FGF3.”
BackgroundLi, X. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0711-y · Cited by 139 · see citing works
“Except for the four FGF-homologous intracrine factors that are functionally reminiscent of the ancestor FGF, the FGFs can be classified into mitogenic and metabolic FGFs, which overtly regulate cellular proliferation and substrate/energy metabolism, respectively, on the basis of their distinct functions and endpoint b…”
BackgroundA review of the evidence for in vivo corneal endothelial regeneration
den Bogerd, B. V., Dhubhghaill, S. N., Koppen, C., Tassignon, M., & Zakaria, N. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.07.004 · Cited by 129 · see citing works
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139 · see citing works
The role of adipokines in skeletal muscle inflammation and insulin sensitivity
Nicholson, T. A., Church, C., Baker, D. J., & Jones, S. W. (2018) · Journal of Inflammation · doi:10.1186/s12950-018-0185-8 · Cited by 126 · see citing works
“NCT01923389) [79–83], and antibodies targeting FGFR1c/ b-Klotho have been developed [84, 85].”
BackgroundEmerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 129 · see citing works
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123 · see citing works
Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine
Tan, H., Tong, Y. A., Chen, Z., Wu, W., Xu, S., & Weng, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73936 · Cited by 119 · see citing works
“To overcome the weak binding affinity and instability of natural FGF21 [127], researchers analysed the structural and dynamic information of FGF21 and developed many FGF chimeras.”
BackgroundFibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Somm, E., & Jornayvaz, F. R. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00134 · Cited by 118 · see citing works
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Boccatonda, A., Andreetto, L., D’Ardes, D., Cocco, G., Rossi, I., Vicari, S., Schiavone, C., Cipollone, F., & Guagnano, M. T. (2023) · Biomedicines · doi:10.3390/biomedicines11030883 · Cited by 113 · see citing works
“Another class of drugs under investigation are fibroblast growth factors (FGFs) 19 and 21 agonists that appear to improve the metabolic endocrine axis involving lipids, glucose and bile acids [92].”
BackgroundFGF1 — a new weapon to control type 2 diabetes mellitus
Gasser, E., Moutos, C. P., Downes, M., & Evans, R. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.78 · Cited by 106 · see citing works
Organ-organ communication: The liver's perspective
Wang, F., So, K., Xiao, J., & Wang, H. (2021) · Theranostics · doi:10.7150/thno.55795 · Cited by 107 · see citing works
“It has been recognized as a therapeutic target of obesity and diabetes [8].”
BackgroundBile acids and colon cancer: Is FXR the solution of the conundrum?
Gadaleta, R. M., García‐Irigoyen, O., & Moschetta, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.002 · Cited by 99 · see citing works
Lu, X., Chen, H., Patterson, A. V., Smaill, J. B., & Ding, K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01531 · Cited by 99 · see citing works
Lang, L., & Teng, Y. (2019) · Cells · doi:10.3390/cells8010031 · Cited by 98 · see citing works
Restelli, L. M., Oettinghaus, B., Halliday, M., Ağca, C., Licci, M., Sironi, L., Savoia, C., Hench, J., Tolnay, M., Neutzner, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.023 · Cited by 96 · see citing works
Tiong, K. H., Tan, B. S., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Khor, N. T., Wong, S. F., See, S.-J., Tan, Y.-F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9328 · Cited by 93 · see citing works
“The significance of FGFs/ FGFRs signaling deregulation in breast cancers has been documented in several studies [13, 48, 49].”
BackgroundPathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 97 · see citing works
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology · doi:10.1002/hep.31523 · Cited by 88 · see citing works
“Fibroblast growth factor receptor 19 (FGF19) is a gut hormone that plays a central role in regulating bile acid metabolism.(17,18) Through the FGFR4-KLB receptor, FGF19 potently suppresses cholesterol 7alpha-hydroxylase (CYP7A1), which encodes the first and rate-liming enzyme in de novo synthesis of bile acids.”
BackgroundCellular Mechanisms of FGF-Stimulated Tissue Repair
Prudovsky, I. (2021) · Cells · doi:10.3390/cells10071830 · Cited by 77 · see citing works
“Another group (FGF 15/19, 21 and 23) consists of secreted hormone-like proteins regulating various aspects of organism metabolism [3].”
BackgroundThe FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
Santolla, M. F., & Maggiolini, M. (2020) · Cancers · doi:10.3390/cancers12103029 · Cited by 89 · see citing works
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Cao, R. Y., Tian, H., Zhang, Y., Liu, G., Xu, H., Rao, G., Tian, Y., & Fu, X. (2023) · MedComm · doi:10.1002/mco2.283 · Cited by 87 · see citing works
Li, C., Chen, T., Liu, J., Wang, Y., Zhang, C., Guo, L., Shi, D., Zhang, T., Wang, X., & Li, J. (2023) · Advanced Science · doi:10.1002/advs.202302613 · Cited by 87 · see citing works
Effects of Periodic Fasting on Fatty Liver Index—A Prospective Observational Study
Drinda, S., Grundler, F., Neumann, T. E., Lehmann, T., Steckhan, N., Michalsen, A., & de Toledo, F. W. (2019) · Nutrients · doi:10.3390/nu11112601 · Cited by 85 · see citing works
“Although there is some evidence of impaired ketogenesis during the progression of liver disease to steatohepatitis, therapies that increase hepatic ketogenesis are expected nonetheless to ameliorate NAFLD [38,39].”
BackgroundJouy, S. H., Mohan, S., Scichilone, G., Mostafa, A., & Mahmoud, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12092129 · Cited by 92 · see citing works
Endocrine regulation of circadian physiology
Tsang, A. H. K., Astiz, M., Friedrichs, M., & Oster, H. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0051 · Cited by 82 · see citing works
“Its signals are mediated via its cognate receptors (FGF receptors FGFR1c, FGFR2c, or FGFR3c) in complex with β-Klotho abundantly expressed in metabolic tissues (Degirolamo et al. 2016).”
BackgroundLin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 83 · see citing works
Circulating FGF21 Levels in Human Health and Metabolic Disease
Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 82 · see citing works
“, long-acting FGF21 analogues [3] or agonistic antibodies and small peptides targeting beta-klotho (KLΒ) [4], the crucial component of FGF21-receptor signaling complex.”
BackgroundSanyal, A. J., Ling, L., Beuers, U. H., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Hirschfield, G. M. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100255 · Cited by 80 · see citing works
Rinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 79 · see citing works
Obesity: a perfect storm for carcinogenesis
Harris, B. H. L., Macaulay, V. M., Harris, D. A., Klenerman, P., Karpe, F., Lord, S., Harris, A. L., & Buffa, F. M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10046-2 · Cited by 80 · see citing works
“Conversely, FGF19 has been reported to be at lower levels in obese patient sera and this too may influence liver metabolism [295].”
BackgroundAngptl8 mediates food-driven resetting of hepatic circadian clock in mice
Chen, S., Feng, M., Zhang, S., Dong, Z., Wang, Y., Zhang, W., & Liu, C. (2019) · Nature Communications · doi:10.1038/s41467-019-11513-1 · Cited by 73 · see citing works
Multi-omics profiling: the way toward precision medicine in metabolic diseases
Hu, C., & Jia, W. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab051 · Cited by 74 · see citing works
“Non-genetic markers for NALFD Another FGF family member, FGF19, binds to the FGFR4– b-klotho receptor complex, thus repressing the activation of cholesterol-7a-hydroxylase, sterol regulatory element-binding protein 1C, and cAMP-response element-binding protein, when induced by bile acids or FXR agonists to suppress th…”
BackgroundParacrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects
Lei, Y., Wang, L., Guo, K., Hou, Y., Li, N., Wang, S., Liu, X., Zhao, Q., Zhou, J., Zhao, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27584-y · Cited by 71 · see citing works
Fasting-induced hormonal regulation of lysosomal function
Chen, L., Wang, K., Long, A., Jia, L., Zhang, Y., Deng, H., Li, Y., Han, J., & Wang, Y. (2017) · Cell Research · doi:10.1038/cr.2017.45 · Cited by 71 · see citing works
Babaknejad, N., Nayeri, H., Hemmati, R., Bahrami, S., & Esmaillzadeh, A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0623-2909 · Cited by 70 · see citing works
“It is claimed that FGF15/19 activates ERK 1/2 signaling in adipocytes and increases glucose uptake [7, 8] (▶Fig.”
BackgroundCiaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 73 · see citing works
“FGFs belong to a family of at least 22 proteins with an effect on growth, development, and differentiation [90,94,95].”
BackgroundJin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71 · see citing works
The role of FGF21 in the pathogenesis of cardiovascular disease
Zhang, Y., Liu, D., Long, X.-X., Fang, Q.-C., Jia, W.-P., & Li, H.-T. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001890 · Cited by 68 · see citing works
“FGFs have therapeutic potential in a wide array of human diseases, including diabetes mellitus (DM),([16]) cancer,([17]) alopecia,([18]) and kidney disease.”
BackgroundVerzijl, C. R. C., van de Peppel, I. P., Struik, D., & Jonker, J. W. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708898 · Cited by 68 · see citing works
“Compared to therapies based on other FGFs, such as FGF1 and FGF19, FGF21 has the advantage of being non-mitogenic [23,58].”
MethodTaming the Flames: Targeting White Adipose Tissue Browning in Hypermetabolic Conditions
Abdullahi, A., & Jeschke, M. G. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00163 · Cited by 67 · see citing works
Engineered biomaterial strategies for controlling growth factors in tissue engineering
Guan, N., Liu, Z., Zhao, Y., Li, Q., & Wang, Y. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831104 · Cited by 66 · see citing works
Phan, P., Saikia, B. B., Sonnaila, S., Agrawal, S., Alraawi, Z., Kumar, T. K. S., & Iyer, S. (2021) · Cells · doi:10.3390/cells10092418 · Cited by 67 · see citing works
“Therefore, the trend of endocrine FGFs research is focused on applying the fundamental knowledge to biomedical and clinical applications where many of them are at various phases of clinical trials (Table 1) [6,9,99,168].”
BackgroundThe role of fibroblast growth factor 21 in atherosclerosis
Kokkinos, J., Tang, S., Rye, K., & Ong, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.033 · Cited by 66 · see citing works
Guo, A., Li, K., & Xiao, Q. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.002 · Cited by 66 · see citing works
Translational Advances in Pediatric Nutrition and Gastroenterology: New Insights from Pig Models
Burrin, D. G., Sangild, P. T., Stoll, B., Thymann, T., Buddington, R. K., Marini, J. C., Olutoye, O. O., & Shulman, R. J. (2020) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-020518-115142 · Cited by 63 · see citing works
FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro
Zhang, S., Yu, D., Wang, M., Huang, T., Wu, H., Zhang, Y., Zhang, T., Wang, W., Yin, J., Ren, G., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.100 · Cited by 62 · see citing works
Struik, D., Dommerholt, M. B., & Jonker, J. W. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000599 · Cited by 61 · see citing works
Epigenetic Regulation of Hepatic Lipid Metabolism by DNA Methylation
Wang, S., Zha, L., Cui, X., Yeh, Y., Liu, R., Jing, J., Shi, H., Chen, W., Hanover, J. A., Yin, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206068 · Cited by 59 · see citing works
Kim, Y., Byun, S., Seok, S., Guo, G. L., Xu, H. E., KEMPER, B. W., & Kemper, J. K. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.061 · Cited by 60 · see citing works
Heianza, Y., Ma, W., Huang, T., Wang, T., Zheng, Y., Smith, S. R., Bray, G. A., Sacks, F. M., & Qi, L. (2016) · Diabetes Care · doi:10.2337/dc16-1111 · Cited by 59 · see citing works
“FGF21 has been attracting great interest as a whole-body metabolic regulator of energy balance and adipose metabolism (10,11) and also as a therapeutic potential for treatment of obesity (10).”
BackgroundTargeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13767 · Cited by 60 · see citing works
- Authors
- Degirolamo, C., Sabbà, C., & Moschetta, A.
- Affiliations
- Istituto Tumori Bari (IT)
- University of Bari Aldo Moro (IT)
- Corresponding author
- Moschetta, Antonio
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-11-16
- Volume
- 15
- Issue
- 1
- Pages
- 51-69
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2214871873
- Cited by
- 424
- References
- 240
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 36 · 2023: 42 · 2022: 55 · 2021: 48 · 2020: 54 · 2019: 43 · 2018: 41 · 2017: 36 · 2016: 18
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Rheumatology › Folate and B Vitamins Research
- Keywords
- FGF19, FGF21, fibroblast growth factor 23, bile acid metabolism, glucose metabolism, lipid metabolism, vitamin D homeostasis, phosphate homeostasis, obesity, type 2 diabetes, cancer, kidney disease, cardiovascular disease
- MeSH terms
- Fibroblast Growth Factor-23, Animals, Chronic Disease, Fibroblast Growth Factors, Homeostasis, Humans, Models, Biological, Drugs, Investigational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
